| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Atacand Receives FDA Approval For Hypertension WAYNE, PA -- June 5, 1998 -- The United States Food and Drug Administration has approved Astra Merck Inc.’s Atacand(R) (candesartan cilexetil) for once-daily treatment of hypertension. Atacand belongs to a group of antihypertensive medications called angiotensin II receptor blockers (ARB) which represent the first new class of antihypertensive agents in the U.S. in more than a decade. In clinical trials involving more than 7000 hypertensive patients, Atacand has been shown to reduce blood pressure in a consistent and dose-dependent manner over a 24-hour period. In clinical trials, treatment with Atacand has been well tolerated with an adverse event rate similar to placebo. Adverse experiences that occurred in at least one percent of patients treated with Atacand and at a higher incidence versus placebo included back pain, dizziness, upper respiratory tract infection, pharyngitis and rhinitis. Atacand should not be used in women who are pregnant or by people who are allergic to any component of the medication. Atacand has been available in a number of European countries since 1997 and is also being studied to explore its use in other cardiovascular disorders.
|